Despite the great potential of mesenchymal stem cells in various regeneration therapies, their application to treat myocardial infarction (MI)–induced hearts is limited. In recent research by an international joint research team of POSTECH, Seoul St. Mary’s Hospital, and City University of Hong Kong, MSCs isolated from human bone marrow are coencapsulated with genetically engineered
HGF-MSCs that continuously secrete hepatocyte growth factor. A 3D bioprinted patch comprising these cells showed that in vivo priming of human mesenchymal stem cells results in their higher viability as well as augmented angiogenesis through secretion of effective factors that cause restoration of injured myocardium and heart function
